Literature DB >> 10428906

Moderate-level resistance to glycopeptide LY333328 mediated by genes of the vanA and vanB clusters in enterococci.

M Arthur1, F Depardieu, P Reynolds, P Courvalin.   

Abstract

Three of five natural plasmids carrying a wild-type vanA gene cluster did not confer LY333328 glycopeptide resistance on Enterococcus faecalis JH2-2 (MIC = 2 microg/ml). The two remaining plasmids conferred resistance to the drug (MIC, 8 microg/ml). The vanB gene cluster did not confer resistance to LY333328, since this antibiotic was not an inducer. Mutations in the vanS(B) sensor gene that allowed induction by teicoplanin or constitutive expression of the vanB cluster led to LY333328 resistance (MIC, 8 to 16 microg/ml). Overproduction of the VanH, VanA, and VanX proteins for D-alanyl-D-lactate (D-Ala-D-Lac) synthesis and D-Ala-D-Ala hydrolysis was sufficient for resistance to LY333328 (MIC, 16 microg/ml). Mutations in the host D-Ala:D-Ala ligase contributed to LY333328 resistance in certain VanA- and VanB-type strains, but the MICs of the antibiotic did not exceed 16 microg/ml. Addition of D-2-hydroxybutyrate in the culture medium of mutants that did not produce the VanH D-lactate dehydrogenase led to incorporation of this D-2-hydroxy acid at the C-terminal ends of the peptidoglycan precursors and to LY333328 resistance (MIC, 64 microg/ml). The vanZ gene of the vanA cluster conferred resistance to LY333328 (MIC, 8 microg/ml) by an unknown mechanism. These data indicate that VanA- and VanB-type enterococci may acquire moderate-level resistance to LY333328 (MIC </= 16 microg/ml) in a single step by various mechanisms.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10428906      PMCID: PMC89384     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  35 in total

1.  An inocula replicating apparatus for routine testing of bacterial susceptibility to antibiotics.

Authors:  E STEERS; E L FOLTZ; B S GRAVES
Journal:  Antibiot Chemother (Northfield)       Date:  1959-05

2.  Mutations leading to increased levels of resistance to glycopeptide antibiotics in VanB-type enterococci.

Authors:  M Baptista; F Depardieu; P Reynolds; P Courvalin; M Arthur
Journal:  Mol Microbiol       Date:  1997-07       Impact factor: 3.501

3.  Requirement of the VanY and VanX D,D-peptidases for glycopeptide resistance in enterococci.

Authors:  M Arthur; F Depardieu; L Cabanié; P Reynolds; P Courvalin
Journal:  Mol Microbiol       Date:  1998-11       Impact factor: 3.501

Review 4.  The structure and mode of action of glycopeptide antibiotics of the vancomycin group.

Authors:  J C Barna; D H Williams
Journal:  Annu Rev Microbiol       Date:  1984       Impact factor: 15.500

5.  The VanS-VanR two-component regulatory system controls synthesis of depsipeptide peptidoglycan precursors in Enterococcus faecium BM4147.

Authors:  M Arthur; C Molinas; P Courvalin
Journal:  J Bacteriol       Date:  1992-04       Impact factor: 3.490

6.  Molecular interactions of a semisynthetic glycopeptide antibiotic with D-alanyl-D-alanine and D-alanyl-D-lactate residues.

Authors:  N E Allen; D L LeTourneau; J N Hobbs
Journal:  Antimicrob Agents Chemother       Date:  1997-01       Impact factor: 5.191

7.  N-alkyl-substituted glycopeptide antibiotics.

Authors:  I Chopra
Journal:  Expert Opin Investig Drugs       Date:  1997-03       Impact factor: 6.206

8.  In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide.

Authors:  F Biavasco; C Vignaroli; R Lupidi; E Manso; B Facinelli; P E Varaldo
Journal:  Antimicrob Agents Chemother       Date:  1997-10       Impact factor: 5.191

9.  Inducible and constitutive expression of resistance to glycopeptides and vancomycin dependence in glycopeptide-resistant Enterococcus avium.

Authors:  A Rosato; J Pierre; D Billot-Klein; A Buu-Hoi; L Gutmann
Journal:  Antimicrob Agents Chemother       Date:  1995-04       Impact factor: 5.191

10.  Modifications of the acyl-D-alanyl-D-alanine terminus affecting complex-formation with vancomycin.

Authors:  M Nieto; H R Perkins
Journal:  Biochem J       Date:  1971-08       Impact factor: 3.857

View more
  24 in total

Review 1.  Regulation of VanA- and VanB-type glycopeptide resistance in enterococci.

Authors:  M Arthur; R Quintiliani
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

Review 2.  Modes and modulations of antibiotic resistance gene expression.

Authors:  Florence Depardieu; Isabelle Podglajen; Roland Leclercq; Ekkehard Collatz; Patrice Courvalin
Journal:  Clin Microbiol Rev       Date:  2007-01       Impact factor: 26.132

3.  In vitro activities of LY333328 and comparative agents against nosocomial gram-positive pathogens collected in a 1997 global surveillance study.

Authors:  M L Zeckel; D A Preston; B S Allen
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

Review 4.  Approved Glycopeptide Antibacterial Drugs: Mechanism of Action and Resistance.

Authors:  Daina Zeng; Dmitri Debabov; Theresa L Hartsell; Raul J Cano; Stacy Adams; Jessica A Schuyler; Ronald McMillan; John L Pace
Journal:  Cold Spring Harb Perspect Med       Date:  2016-12-01       Impact factor: 6.915

5.  Unmet needs and prospects for oritavancin in the management of vancomycin-resistant enterococcal infections.

Authors:  Cesar A Arias; Rodrigo E Mendes; Matthew G Stilwell; Ronald N Jones; Barbara E Murray
Journal:  Clin Infect Dis       Date:  2012-04       Impact factor: 9.079

6.  Structural variations of the cell wall precursor lipid II and their influence on binding and activity of the lipoglycopeptide antibiotic oritavancin.

Authors:  Daniela Münch; Ina Engels; Anna Müller; Katrin Reder-Christ; Hildegard Falkenstein-Paul; Gabriele Bierbaum; Fabian Grein; Gerd Bendas; Hans-Georg Sahl; Tanja Schneider
Journal:  Antimicrob Agents Chemother       Date:  2014-11-17       Impact factor: 5.191

Review 7.  New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin.

Authors:  George G Zhanel; Divna Calic; Frank Schweizer; Sheryl Zelenitsky; Heather Adam; Philippe R S Lagacé-Wiens; Ethan Rubinstein; Alfred S Gin; Daryl J Hoban; James A Karlowsky
Journal:  Drugs       Date:  2010-05-07       Impact factor: 9.546

Review 8.  Glycopeptide antibiotics: from conventional molecules to new derivatives.

Authors:  Françoise Van Bambeke; Yves Van Laethem; Patrice Courvalin; Paul M Tulkens
Journal:  Drugs       Date:  2004       Impact factor: 9.546

9.  Vancomycin and oritavancin have different modes of action in Enterococcus faecium.

Authors:  Gary J Patti; Sung Joon Kim; Tsyr-Yan Yu; Evelyne Dietrich; Kelly S E Tanaka; Thomas R Parr; Adel Rafai Far; Jacob Schaefer
Journal:  J Mol Biol       Date:  2009-07-01       Impact factor: 5.469

Review 10.  VanD-type vancomycin-resistant Enterococcus faecium 10/96A.

Authors:  Florence Depardieu; Peter E Reynolds; Patrice Courvalin
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.